A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2014
This article has no abstract
Epistemonikos ID: 9a88862f942d0d4af9206fe423e90c0dc77afa68
First added on: Apr 17, 2025